Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease


Opinion

Buzz on the Bullboards: Defying the Markets

Omri Wallach August 16, 2019

Buzz on the Bullboards: Who’s Hot and Who’s Not

Stockhouse Editorial April 12, 2019

Buzz on the Bullboards: Snapshot of Recent Winners/Losers

Stockhouse Editorial February 11, 2019

Buzz on the Bullboards: Investing Success in 2019?

Stockhouse Editorial January 11, 2019

VIDEO: Help for Bladder Cancer Patients

BTV-Business Television July 24, 2018

Buzz on the Bullboards: Hottest Summer Stocks and Trends

Stockhouse Editorial June 21, 2018

Latest Bullboard Posts

links

Theralase Technologies (TSXV: TLT) @TheralaseTech · Oct 10...
winr88 - 3 hours ago

RE:RE:RE:RE:RE:RE:Trading today

lets put the politics too bed boys...quit the b.s.
sparky5 - 3 hours ago

RE:RE:RE:US markets are open

you must be amarican
sparky5 - 4 hours ago

RE:RE:RE:RE:RE:Trading today

I'm with you on this one Pandora, anybody who still supports any of the current Democratics on the ticket, have absolute rocks in...
Yajne - 4 hours ago

You do have a point Pandora

With a population well over 300 million is that the best they can do , then again nearly anyone would do better than what they have now.
silverT - 4 hours ago

RE:RE:RE:RE:RE:Trading today

I was being gentle with the sap.....those were easy guesses
silverT - 5 hours ago

follow V.TLT on

CORPORATE PRESENTATION

MEDIA

MANAGEMENT




  1. Oversubscribed Prospectus Offering. The Company has successfully completed an oversubscribed marketed public offering ("Offering") on August 22, 2019, raising gross proceeds of CAD $17,250,000.
     
  2. Successful Phase Ib NMIBC Clinical Study.
     
  3. Phase II Clinical Study advancement, 2 patients treated
     
  4. FDA compliance. In June 2019, FDA confirmed in the Pre-Investigational New Drug ("IND") conference call, that Theralase's protocol design for Study II is aligned with the industry guidelines (February, 2018) for Bacillus Calmette Guerin ("BCG")-unresponsive NMIBC.
     

IR CONTACT

1.866.THE.LASE (843-5273)
416.699.LASE (5273)

Shushu Feng, Investor Relations & Public Relations Coordinator
sfeng@theralase.com

Amelia Tudo, Investor Relations & Public Relations Coordinator
atudo@theralase.com



×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.